您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > LXS196
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LXS196
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LXS196图片
CAS NO:1874276-76-2
规格:98%
分子量:472.47
包装与价格:
包装价格(元)
2mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
LXS196是有效的、选择性的和具有口服活性的蛋白激酶C(PKC)抑制剂,对PKCα、PKCθ和GSK3β的IC50值分别为1.9nM、0.4nM和3.1μM。可用于治疗葡萄膜黑素瘤。
CAS:1874276-76-2
分子式:C22H23F3N8O
分子量:472.47
纯度:98%
存储:Store at -20°C

Background:

LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma[1][2].


Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1].


LXS196 (compound 9) (15, 30, 75, 150 mg/kg, P.O., mice) shows improved efficacy (regression) in a 92.1 GNAQ uveal melanoma xenograft model in a dose-dependently manner[2].|| Animal Model:|Mice implanted with 92.1 GNAQ mutant uveal melanoma cells[2].|Dosage:|15, 30, 75, 150 mg/kg|Administration:|P.O. (bid) for 35 days|Result:|Dose-dependently suppressed the tumor growth.


[1]. Protein Kinase C Inhibitor LXS196 [2]. US20180179181.